Overexpressed TP73 induces apoptosis in medulloblastoma

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Castellino, Robert C ^a   De Bortoli, Massimiliano ^a   Lin, Linda L ^a   Skapura, Darlene G ^a   Rajan, Jessen A ^a   Adesina, Adekunle M ^a   Perlaky, Laszlo ^a   Irwin, Meredith S ^b   Kim, John Y H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PROTEIN P73; RNA; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TP73 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE; CELL SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; KNOCKOUT GENE; MALE; MEDULLOBLASTOMA; NICK END LABELING; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; CEREBELLUM TUMOR; DISEASE COURSE; FOLLOW UP; GENE SILENCING; GENETICS; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RETROSPECTIVE STUDY; TIME; TUMOR CELL LINE;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INFANT; MALE; MEDULLOBLASTOMA; NUCLEAR PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 34548354662     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-127     Document Type: Article

References (55)

1. Giangaspero F Bigner SH Giordana MT Kleihues P Trojanowski JQ Medulloblastoma Pathology and Genetics: Tumours of the Nervous System. World Health Organization Classification of Tumours Lyon, France: International Agency for Research of Cancer Kleihues P, Cavenee WK 2000 96-103
2. McNeil DE Cote TR Clegg L Rorke LB Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Surveillance Epidemiology and End Results Med Pediatr Oncol 2002 39 3 190-194 10.1002/mpo.10121 12210449
3. Rood BR Macdonald TJ Packer RJ Current treatment of medulloblastoma: recent advances and future challenges Semin Oncol 2004 31 5 666-675 10.1053/j.seminoncol.2004.07.009 15497120
4. Benard J Douc-Rasy S Ahomadegbe JC TP53 family members and human cancers Hum Mutat 2003 21 3 182-191 10.1002/humu.10172 12619104
5. Ohgaki H Eibl RH Wiestler OD Yasargil MG Newcomb EW Kleihues P p53 mutations in nonastrocytic human brain tumors Cancer Res 1991 51 22 6202-6205 1933879
6. Oren M Decision making by p53: Life, death and cancer Cell Death Differ 2003 10 4 431-442 10.1038/sj.cdd.4401183 12719720
7. Saylors RL 3rd Sidransky D Friedman HS Bigner SH Bigner DD Vogelstein B Brodeur GM Infrequent p53 gene mutations in medulloblastomas Cancer Res 1991 51 17 4721-4723 1873817
8. Frank AJ Hernan R Hollander A Lindsey JC Lusher ME Fuller CE Clifford SC Gilbertson RJ The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma Brain Res Mol Brain Res 2004 121 1-2 137-140 10.1016/j.molbrainres.2003.11.016 14969745
9. Eberhart CG Chaudhry A Daniel RW Khaki L Shah KV Gravitt PE Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus BMC Cancer 2005 5 19 554768 15717928 10.1186/1471-2407-5-19
10. Wetmore C Eberhart DE Curran T Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched Cancer Res 2001 61 2 513-516 11212243
11. Biegel JA Cytogenetics and molecular genetics of childhood brain tumors Neuro-oncol 1999 1 2 139-151 10.1215/15228517-1-2-139 11550309 1920753
12. Ellison D Classifying the medulloblastoma: Insights from morphology and molecular genetics Neuropathol Appl Neurobiol 2002 28 4 257-282 10.1046/ j.1365-2990.2002.00419.x 12175339
13. Kaghad M Bonnet H Yang A Creancier L Biscan JC Valent A Minty A Chalon P Lelias JM Dumont X Ferrara P McKeon F Caput D Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers Cell 1997 90 4 809-819 10.1016/ S0092-8674(00)80540-1 9288759
14. Pozniak CD Radinovic S Yang A McKeon F Kaplan DR Miller FD An anti-apoptotic role for the p53 family member, p73, during developmental neuron death Science 2000 289 5477 304-306 10.1126/science.289.5477.304 10894779
15. Jacobs WB Walsh GS Miller FD Neuronal survival and p73/p63/p53: A family affair Neuroscientist 2004 10 5 443-455 10.1177/1073858404263456 15359011
16. Concin N Becker K Slade N Erster S Mueller-Holzner E Ulmer H Daxenbichler G Zeimet A Zeillinger R Marth C Moll UM Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo Cancer Res 2004 64 7 2449-2460 10.1158/0008-5472.CAN-03-1060 15059898
17. Concin N Hofstetter G Berger A Gehmacher A Reimer D Watrowski R Tong D Schuster E Hefler L Heim K Mueller-Holzner E Marth C Moll UM Zeimet AG Zeillinger R Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: Evidence for a crucial p53-p73 cross-talk in vivo Clin Cancer Res 2005 11 23 8372-8383 10.1158/1078-0432.CCR-05-0899 16322298
18. Dominguez G Garcia JM Pena C Silva J Garcia V Martinez L Maximiano C Gomez ME Rivera JA Garcia-Andrade C Bonilla F DeltaTAp73 upregulation correlates with poor prognosis in human tumors: Putative in vivo network involving p73 isoforms, p53, and E2F-1 J Clin Oncol 2006 24 5 805-815 10.1200/JCO.2005.02.2350 16380414
19. Guan M Chen Y Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: Correlation with Gleason score J Clin Pathol 2005 58 11 1175-1179 10.1136/jcp.2005.026955 16254107
20. Ishimoto O Kawahara C Enjo K Obinata M Nukiwa T Ikawa S Possible oncogenic potential of DeltaNp73: A newly identified isoform of human p73 Cancer Res 2002 62 3 636-641 11830511
21. Stiewe T Zimmermann S Frilling A Esche H Putzer BM Transactivation-deficient DeltaTA-p73 acts as an oncogene Cancer Res 2002 62 13 3598-3602 12097259
22. Zaika AI Slade N Erster SH Sansome C Joseph TW Pearl M Chalas E Moll UM DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors J Exp Med 2002 196 6 765-780 10.1084/ jem.20020179 12235210
23. Alonso ME Bello MJ Gonzalez-Gomez P Lomas J Arjona D de Campos JM Kusak ME Sarasa JL Isla A Rey JA Mutation analysis of the p73 gene in nonastrocytic brain tumours Br J Cancer 2001 85 2 204-208 10.1054/ bjoc.2001.1855 11461077
24. Blaney SM Boyett J Friedman H Gajjar A Geyer R Horowtiz M Hunt D Kieran M Kun L Packer R Adamson PC Jaeckle K Klenke R Aikin A Murphy R McCully C Poplack DG Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001) J Clin Oncol 2005 23 3 525-531 10.1200/JCO.2005.06.544 15659498
25. Duffner PK Horowitz ME Krischer JP Burger PC Cohen ME Sanford RA Friedman HS Kun LE The treatment of malignant brain tumors in infants and very young children: An update of the Pediatric Oncology Group experience Neuro-oncol 1999 1 2 152-161 10.1215/15228517-1-2-152 11554387 1920752
26. Packer RJ Goldwein J Nicholson HS Vezina LG Allen JC Ris MD Muraszko K Rorke LB Wara WM Cohen BH Boyett JM Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study J Clin Oncol 1999 17 7 2127-2136 10561268
27. Strother D Ashley D Kellie SJ Patel A Jones-Wallace D Thompson S Heideman R Benaim E Krance R Bowman L Gajjar A Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: Results of a collaborative study J Clin Oncol 2001 19 10 2696-2704 11352962
28. IARC TP53 Mutation Database http://www-p53.iarc.fr/
29. Sanger Center Cancer Cell Line Project http://www.sanger.ac.uk/genetics/ CGP/CellLines/
30. Pfaffl MW A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 2001 29 9 e45 55695 11328886 10.1093/ nar/29.9.e45
31. De Laurenzi V Costanzo A Barcaroli D Terrinoni A Falco M Annicchiarico-Petruzzelli M Levrero M Melino G Two new p73 splice variants, gamma and delta, with different transcriptional activity J Exp Med 1998 188 9 1763-1768 10.1084/jem.188.9.1763 9802988
32. Irwin MS Kondo K Marin MC Cheng LS Hahn WC Kaelin WG Jr Chemosensitivity linked to p73 function Cancer Cell 2003 3 4 403-410 10.1016/ S1535-6108(03)00078-3 12726865
33. Marin MC Jost CA Irwin MS DeCaprio JA Caput D Kaelin WG Jr Viral oncoproteins discriminate between p53 and the p53 homolog p73 Mol Cell Biol 1998 18 11 6316-6324 109218 9774648
34. Lin KW Nam SY Toh WH Dulloo I Sabapathy K Multiple stress signals induce p73beta accumulation Neoplasia 2004 6 5 546-557 1531659 15548364 10.1593/ neo.04205
35. Sayan AE Paradisi A Vojtesek B Knight RA Melino G Candi E New antibodies recognizing p73: Comparison with commercial antibodies Biochem Biophys Res Commun 2005 330 1 186-193 10.1016/j.bbrc.2005.02.145 15781249
36. Brain Gene Expression Map http://www.stjudebgem.org/web/view/probe/ viewProbeDetails.php?id=2588
37. Lee AF Ho DK Zanassi P Walsh GS Kaplan DR Miller FD Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms J Neurosci 2004 24 41 9174-84 10.1523/ JNEUROSCI.1588-04.2004 15483136
38. Pozniak CD Barnabe-Heider F Rymar VV Lee AF Sadikot AF Miller FD p73 is required for survival and maintenance of CNS neurons J Neurosci 2002 22 22 9800-9 12427836
39. Loiseau H Arsaut J Demotes-Mainard J p73 gene transcripts in human brain tumors: Overexpression and altered splicing in ependymomas Neurosci Lett 1999 263 2-3 173-6 10.1016/S0304-3940(99)00130-5 10213163
40. Zaika AI Kovalev S Marchenko ND Moll UM Overexpression of the wild type p73 gene in breast cancer tissues and cell lines Cancer Res 1999 59 13 3257-63 10397274
41. Peters UR Tschan MP Kreuzer KA Baskaynak G Lass U Tobler A Fey MF Schmidt CA Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis Cancer Res 1999 59 17 4233-6 10485463
42. Meyer G Perez-Garcia CG Abraham H Caput D Expression of p73 and Reelin in the developing human cortex J Neurosci 2002 22 12 4973-86 12077194
43. Cabrera-Socorro A Pueyo Morlans M Suarez Sola ML Gonzalez Delgado FJ Castaneyra-Perdomo A Marin MC Meyer G Multiple isoforms of the tumor protein p73 are expressed in the adult human telencephalon and choroid plexus and present in the cerebrospinal fluid Eur J Neurosci 2006 23 8 2109-18 10.1111/j.1460-9568.2006.04750.x 16630058
44. Marabese M Marchini S Sabatino MA Polato F Vikhanskaya F Marrazzo E Riccardi E Scanziani E Broggini M Effects of inducible overexpression of DNp73alpha on cancer cell growth and response to treatment in vitro and in vivo Cell Death Differ 2005 12 7 805-814 10.1038/sj.cdd.4401622 15877106
45. Irwin MS Kondo K Marin MC Cheng LS Hahn WC Kaelin WG Jr Chemosensitivity linked to p73 function Cancer Cell 2003 3 4 403-410 10.1016/ S1535-6108(03)00078-3 12726865
46. Vossio S Palescandolo E Pediconi N Moretti F Balsano C Levrero M Costanzo A DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest Oncogene 2002 21 23 3796-3803 10.1038/sj.onc.1205465 12032848
47. Irwin MS DeltaNp73: Misunderstood protein? Cancer Biol Ther 2006 5 7 804-7 Epub 2006 Jul 14 16921261
48. Nam C Yamauchi H Nakayama H Doi K Etoposide induces apoptosis and cell cycle arrest of neuroepithelial cells in a p53-related manner Neurotoxicol Teratol 2006 28 6 664-672 10.1016/j.ntt.2006.09.021 17095187
49. Clifford B Beljin M Stark GR Taylor WR G2 arrest in response to topoisomerase II inhibitors: The role of p53 Cancer Res 2003 63 14 4074-4081 12874009
50. Attardi LD de Vries A Jacks T Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer Oncogene 2004 23 4 973-980 10.1038/sj.onc.1207026 14749764
51. Di Como CJ Gaiddon C Prives C p73 function is inhibited by tumor-derived p53 mutants in mammalian cells Mol Cell Biol 1999 19 2 1438-1449 116072 9891077
52. Blaheta RA Michaelis M Natsheh I Hasenberg C Weich E Relja B Jonas D Doerr HW Cinatl J Jr Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium Br J Cancer 2007 May 15 17505515
53. Lunghi P Costanzo A Salvatore L Noguera N Mazzera L Tabilio A Lo-Coco F Levrero M Bonati A MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis Blood 2006 107 11 4549-53 Epub 2006 Feb 7 10.1182/blood-2005-07-2829 16467208
54. Liu G Nozell S Xiao H Chen X DeltaNp73beta is active in transactivation and growth suppression Mol Cell Biol 2004 24 2 487-501 343790 14701724 10.1128/MCB.24.2.487-501.2004
55. Marrazzo E Marchini S Previdi S Broggini M Questioning the oncogenic role of DeltaNp73alpha in different cell lines expressing p53 or not Cancer Biol Ther 2006 5 7 794-803 Epub 2006 Jul 28 16721041